ArticleFrontiers in pharmacology2023
Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.Aging clinical and experimental research · 2025Pooled it
- Testosterone replacement therapy and cardiovascular safety in older men: lessons from TRAVERSE and beyond.Journal of endocrinological investigation · 2026Review
- The Role of Testosterone in Atherosclerosis: View From Cell Cultures and Animal Models.Journal of cardiovascular translational research · 2026Review
- Real-world FAERS safety analysis of Pralsetinib.Scientific reports · 2025Article
- A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2025Article
- The Use of Anabolic Steroids by Bodybuilders in the State of Sergipe, Brazil.European journal of investigation in health, psychology and education · 2024Article
- Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis.Frontiers in pharmacology · 2024Article
- Assessing the safety of bedaquiline: insight from adverse event reporting system analysis.Frontiers in pharmacology · 2024Article
- Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration.Frontiers in pharmacology · 2024Article
- Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.